116 related articles for article (PubMed ID: 11105832)
1. Quantifying the radiation exposure of nursing staff delivering hyperbaric oxygen therapy to grade IV neuroblastoma patients post 131I-MIBG therapy.
Melbourne GJ; Lehm JP
Eur J Nucl Med; 2000 Nov; 27(11):1732-3. PubMed ID: 11105832
[No Abstract] [Full Text] [Related]
2. [131I meta-iodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma].
Stanková J; Kavan P; Krízová H; Hermanská E; Dosel P; Sázel M
Cas Lek Cesk; 2001 Jan; 140(1):13-7. PubMed ID: 11242978
[TBL] [Abstract][Full Text] [Related]
3. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
[TBL] [Abstract][Full Text] [Related]
4. Radiation exposure in nurses during care of
Taniguchi Y; Wakabayashi H; Inaki A; Kayano D; Yamada M; Kinuya S
Ann Nucl Med; 2020 Jun; 34(6):441-447. PubMed ID: 32297135
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma therapy using radiolabelled [131I]meta-iodobenzylguanidine ([131I]MIBG) in combination with other agents.
Mairs RJ
Eur J Cancer; 1999 Aug; 35(8):1171-3. PubMed ID: 10615225
[No Abstract] [Full Text] [Related]
6. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV.
Voûte PA; van der Kleij AJ; De Kraker J; Hoefnagel CA; Tiel-van Buul MM; Van Gennip H
Eur J Cancer; 1995; 31A(4):596-600. PubMed ID: 7576976
[TBL] [Abstract][Full Text] [Related]
8. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status.
Tepmongkol S; Heyman S
Med Pediatr Oncol; 1999 Jun; 32(6):427-31; discussion 432. PubMed ID: 10358701
[TBL] [Abstract][Full Text] [Related]
9. Nuclear medicine therapy of neuroblastoma.
Hoefnagel CA
Q J Nucl Med; 1999 Dec; 43(4):336-43. PubMed ID: 10731784
[TBL] [Abstract][Full Text] [Related]
10. Application of a tungsten apron for occupational radiation exposure in nursing care of children with neuroblastoma during
Taniguchi Y; Wakabayashi H; Yoneyama H; Chen Z; Morino K; Otosaki A; Yamada M; Inaki A; Kayano D; Kinuya S
Sci Rep; 2022 Jan; 12(1):47. PubMed ID: 34996922
[TBL] [Abstract][Full Text] [Related]
11. Hyperbaric oxygen enhances the effects of meta-iodobenzylguanidine (MIBG) on energy metabolism and lipid peroxidation in the human neuroblastoma cell line SK-N-BE(2C).
Cornelissen J; Van Kuilenburg AB; Elzinga L; Van der Kleij AD; Voûte PA; Van Gennip AH
Anticancer Res; 1997; 17(1A):259-64. PubMed ID: 9066662
[TBL] [Abstract][Full Text] [Related]
12. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
13. Combined use of chemotherapy and 131I-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma.
Sari O; Uğur O; Emir S; Akyüz C
Turk J Pediatr; 2001; 43(1):29-33. PubMed ID: 11297155
[TBL] [Abstract][Full Text] [Related]
14. Primary ovarian insufficiency in children after treatment with 131I-metaiodobenzylguanidine for neuroblastoma: report of the first two cases.
Clement SC; Kraal KC; van Eck-Smit BL; van den Bos C; Kremer LC; Tytgat GA; van Santen HM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E112-6. PubMed ID: 24187404
[TBL] [Abstract][Full Text] [Related]
15. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
16. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
17. HIGH-DOSE 131I-MIBG THERAPIES IN CHILDREN: FEASIBILITY, PATIENT DOSIMETRY AND RADIATION EXPOSURE TO WORKERS AND FAMILY CAREGIVERS.
Cougnenc O; Defachelles AS; Carpentier P; Lervat C; Clisant S; Oudoux A; Kolesnikov-Gauthier H
Radiat Prot Dosimetry; 2017 Apr; 173(4):395-404. PubMed ID: 26940442
[TBL] [Abstract][Full Text] [Related]
18. Treatment of recurrent stage IV neuroblastomas with 131I-MIBG and HBO Six years follow-up.
van der Kleij AJ; Voûte PA
Strahlenther Onkol; 1996 Nov; 172 Suppl 2():28-9. PubMed ID: 8946044
[No Abstract] [Full Text] [Related]
19. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor.
Kono Y; Shimizu Y; Wakatsuki Y; Yasui N; Aso T; Kawamoto H; Kurihara H
Radiat Prot Dosimetry; 2015 Mar; 163(4):533-4. PubMed ID: 25227441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
